Logo-npj
Submitted: 24 Jun 2022
Accepted: 22 Jan 2023
ePublished: 17 Feb 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2023;12(2): e10506.
doi: 10.34172/npj.2023.10506

Scopus ID: 85162014634
  Abstract View: 1573
  PDF Download: 437

Original

A study on the effect of aspirin on clinical symptoms, laboratory indices, and outcomes in patients with COVID-19

Roham Azizi 1 ORCID logo, Maryam Dehghani Mobarakeh 2 ORCID logo, Reza Goujani 3 ORCID logo, Mohsen Nabi-Afjadi 4 ORCID logo, Soheil Mousavi Rizi 1 ORCID logo, Ahmadreza Maghsoudi 5* ORCID logo

1 Department of Occupational Health and Safety Engineering, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran
2 Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran
3 Modeling in Health Research Center, Shahrekord University of Medical Siences, Shahrekord, Iran
4 Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
5 Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
*Corresponding Author: Ahmadreza Maghsoudi, Email: ahmaghsoudi@med.mui.ac.ir,, Email: dr_maghsoudi_md@yahoo.com

Abstract

Introduction: Low-dose aspirin is one of the most widely used secondary prevention agents for cardiovascular disease and stroke. An unstable risk factor for chronic cardiovascular disease is a viral infection. Evidence suggests that the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could increase the risk of acute cardiovascular events by inducing systemic inflammatory responses and instability in coronary plaques.

Objectives: The present study aimed to examine the impact of aspirin on clinical symptoms, laboratory indices, and clinical outcomes in patients with COVID-19.

Patients and Methods: After reviewing the documents of hospitalized patients at the Dr. Shariati hospital in Isfahan, Iran, while case and control groups were selected using a cross-sectional method based on aspirin use and non-use. Following a random selection of the reference population (131 medical records of patients with COVID-19 who had aspirin use and 131 of the group of patients with COVID-19 without aspirin use). Medical records of patients with cardiovascular disease, diabetes, cardiovascular disease with diabetes, and patients without underlying disease were evaluated. After matching the two groups based on age, gender, and medical history, the examination and results were recorded in a questionnaire.

Results: The results showed that during treatment, no significant difference between the case and control groups regarding clinical symptoms, laboratory results, the need for bilevel positive airway pressure (BiPAP), and mechanical ventilation (P=0.0111 and P=0.089, respectively) were observed. Moreover, no significant difference in the outcome, including improvement and death was detected (P=0.962). Likewise, no significant difference in hospitalization duration between the aspirin and control groups was seen (P=0.289).

Conclusion: Our study on a group of COVID-19 patients showed, aspirin is ineffective on clinical symptoms, laboratory indices, and outcomes, however our results further investigation by multi-centric investigations.


Implication for health policy/practice/research/medical education:

In a cross-sectional and observational study, the case and control groups were selected based on aspirin use, with non-users divided into two groups (131 medical records of patients with COVID-19 who administered aspirin and 131 of the group of patients with COVID-19 without aspirin administration). Aspirin was found to be ineffective in treating clinical symptoms, laboratory indices, and outcomes in COVID-19 patients.

Please cite this paper as: Azizi R, Dehghani Mobarakeh M, Goujani R, Nabi-Afjadi M, Mousavi Rizi S, Maghsoudi A. A study on the effect of aspirin on clinical symptoms, laboratory indices, and outcomes in patients with COVID-19. J Nephropharmacol. 2023;12(2):e10506. DOI: 10.34172/npj.2023.10506.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 1574

Your browser does not support the canvas element.


PDF Download: 437

Your browser does not support the canvas element.